You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

mass. movers

Curis stock plunges as drug trial stalls

Curis must provide more safety data to resume testing. Above, a cancer patient gets radiation treatment.

San Antonio Express-News via AP

Curis must provide more safety data to resume testing. Above, a cancer patient gets radiation treatment.

Continue reading below

Curis Inc., which is developing cancer therapies, plunged after the Lexington company unveiled quarterly results and an FDA action. Revenue swelled to $7.2 million, from less than $0.6 million a year earlier, and the net loss shrank by nearly half to $1.9 million. But Curis’s cancer drug CUDC-427 was put on partial hold by the FDA — negating any chance of enrolling new patients in a phase 1 study. A patient died of liver failure a month after the end of CUDC-427 treatment.

Loading comments...
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.